
Background and objective AKT serine/threonine kinase 1 (AKT1) E17K, the most common activating mutation of AKT1, is an established druggable driver in breast cancer; however, it is exceedingly rare in non-small cell lung cancer (NSCLC), with its clinical significance remaining unclear. Variant allele frequency (VAF) may partially reflect the clonal proportion of a mutation, offering clues to the clonal characteristics of such rare mutations. This study investigated the relationship between AKT1 E17K VAF and co-mutation with classic driver genes such as epidermal growth factor receptor (EGFR) in NSCLC, aiming to explore the potential role of this mutation in tumor clonal evolution. Methods Next-generation sequencing (NGS) data of lung cancer patients at Beijing Chest Hospital, Capital Medical University from June 2019 to April 2026 were retrospectively analyzed. After deduplication of 13,003 tests, 11,368 unique patients (including small cell lung cancer) were identified, among whom 35 harbored AKT1 E17K mutations (overall detection rate 0.31%), all being NSCLC; 5 external consultation cases were excluded, leaving 30 cases for analysis. Continuous VAF analysis was designated as the primary analysis, with an exploratory cutoff of 10%. Results Of the 30 patients, 20 (66.7%) were adenocarcinoma. Median follow-up was 12 months (range: 1-55 months). The EGFR co-mutation rate was lower in the high-VAF group (≥10%, n=17) than in the low-VAF group (<10%, n=13; 11.8% vs 46.2%), reaching nominal significance before correction [P=0.049, odds ratio (OR)=0.156] but not after Bonferroni adjustment (adjusted P=0.246). The median VAF was lower in the EGFR co-mutated group than in the EGFR wild-type group (1.37% vs 13.73%, P=0.071). Continuous analysis showed a negative trend between VAF and EGFR co-mutation (ρ=-0.340, P=0.066). After adjusting for histological type using Firth-corrected Logistic regression, the direction of the association remained unchanged but was no longer nominally significant (OR=0.21, 95%CI: 0.03-1.33, P=0.097). Conclusion AKT1 E17K VAF showed a negative trend with EGFR co-mutation; however, the association did not remain significant after correction for multiple comparisons or adjustment for histological type, and may be partly influenced by histological composition. These findings should be regarded as hypothesis-generating and require validation in larger multi-center cohorts.
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign pulmonary tumor that predominantly occurs in middle-aged women. Its preoperative diagnosis remains challenging, and it is frequently misdiagnosed as a malignant tumor. Herein, we report a case of PSP with atypical imaging manifestations and review the current literature on this entity. A 68-year-old woman presented with chest tightness. Chest computed tomography (CT) revealed a lobulated solid nodule in the right middle lobe measuring approximately 26 mm × 22 mm, accompanied by multiple enlarged lymph nodes in the bilateral hilar, mediastinal, and axillary regions. The diagnosis of PSP was confirmed by postoperative histopathology. Based on the features of this case and review of the relevant literature, we suggest that when a patient presents with clinical features suggestive of PSP and intraoperative frozen-section hematoxylin and eosin staining predominantly shows a single solid or papillary architecture in which the surface and stromal cells are difficult to distinguish, intraoperative rapid immunohistochemistry may be performed to improve diagnostic accuracy and avoid excessive surgical resection.
Lung cancer remains the malignant tumor with the highest incidence and mortality rates worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Radical surgical resection serves as the primary curative modality for patients with resectable NSCLC; however, postoperative recurrence persists in a subset of patients, thereby compromising long-term survival outcomes. Consequently, the precise prediction of postoperative recurrence risk, identification of high-risk populations, and formulation of individualized adjuvant therapy and surveillance strategies are of paramount importance for improving patient prognosis. In recent years, fueled by the rapid evolution of artificial intelligence (AI) and liquid biopsy technologies, the prediction of postoperative recurrence in NSCLC has progressively transitioned toward greater precision and personalization. This review summarizes the current applications of traditional predictive models, AI-based models, and liquid biopsy techniques in forecasting NSCLC recurrence following surgery, evaluating their respective strengths and limitations. Furthermore, it provides insights into future research trajectories.
Enteric‑type thymic adenocarcinoma (ETAC) is a rare subtype of thymic carcinoma. It shares highly similar histological and immunophenotypic features with intestinal adenocarcinoma, and is therefore prone to being misdiagnosed as metastatic carcinoma of gastrointestinal origin. Herein, we report a case of advanced ETAC with axillary lymph node oligometastasis. Positron emission tomography/computed tomography (PET/CT) and gastrointestinal endoscopy were performed to rule out primary gastrointestinal malignancy. The patient underwent median sternotomy with extended thymectomy, which effectively relieved superior vena cava obstruction and cardiopulmonary compressive symptoms. Postoperatively, systemic chemotherapy combined with immunotherapy, as well as regional radiotherapy targeting the primary tumor bed and metastatic lymph nodes, were administered. The patient remained disease‑free during the 24‑month postoperative follow‑up. This case suggests that aggressive local therapy combined with molecular‑subtype‑based systemic treatment may offer novel therapeutic opportunities for carefully selected patients with advanced ETAC and oligometastases.
As one of the malignant tumors with high incidence and mortality worldwide, lung cancer features high heterogeneity and therapeutic resistance, which severely impair the prognosis of patients with lung cancer. In recent years, novel cell death modes such as ferroptosis, cuproptosis, disulfidptosis and necrosis by sodium overload have become research hotspots in oncology. Focusing on these four forms of cell death, this review systematically clarifies their roles in lung cancer initiation and progression, regulation of the tumor microenvironment, and therapeutic resistance; summarizes related prognostic biomarkers and representative prognostic models; and discusses the crosstalk among multiple cell death pathways and advances in clinical translation. This review aims to provide a reference for improving prognostic assessment in lung cancer, elucidating mechanisms of therapeutic resistance, and developing novel antitumor strategies.